MarkBellgrove

Mark Andrew Bellgrove

President: BSc (Hons), PhD

I am Professor of Cognitive Neuroscience and Director of Research in the Institute of Cognitive and Clinical Neurosciences at Monash University.  I have over 15 years’ experience in studying the neurobiology of ADHD and am internationally known for my work on the genetics, neuropsychology and pharmacology of ADHD.

In 2014 I commenced discussions with a group of Australian academics and clinicians regarding the formation of a national professional group for ADHD.  In 2017 the Australian Professionals Association was inaugurated and I was installed as the interim President.  I am a strong advocate for evidenced-based diagnosis, treatment and management of ADHD and have a strong vision for the development of unified national diagnosis, prescribing and treatment practices.  Through greater visibility of our Association over the coming years, we will influence policy and ensure a “better deal” for the many individuals affected by ADHD within Australia.

Disclosure: 

Prof. Bellgrove has in the past received a research grant from Eli Lily. He has received grants related to ADHD from the Science Foundation Ireland, the Irish Health Research Board, the National Health and Medical Research Council (NHMRC) Australia, the Murdoch Children’s Research Institute (Australia), National Alliance on Schizophrenia and Allied Disciplines (NARSAD) – US, and the Australian Research Council. He has received an educational grant from Shire. He has given educational talks at meetings sponsored by Janssen-Cilag, Eli Lilly and Shire. Prof. Bellgrove is a founding member and inaugural President of the Australian ADHD Professionals Association.

David Rockwell Coghill

Vice-President

I am an academic child and adolescent psychiatrist working since 2016 at the University of Melbourne and Royal Children’s Hospital Melbourne.

I have a longstanding research and clinical connection to ADHD. My research interests are broad and include basic neuroscience, neuropsychology, neuropsychopharmacology, health services research, implementation science, clinical trials, pharmacovigilance and quality of life. I have been involved in the development and implementation of evidence based pathways for ADHD and in the development of several National and International Clinical guidelines for ADHD.

I am experienced in running ADHD professional groups. I am the chair of EUNETHYDIS International conferences a charity that supports education and research in ADHD and related disorders. I am a longstanding member of the executive committee of the European Network for Hyperkinetic disorders (EUNETHYDIS).

I am committed to the development and implementation of evidence based clinical practice across our field and strongly believe that the Association can make a strong contribution to making this happen.

Disclosure:

Prof. Coghill has received research support from Shire and Vifor Pharma. He has also received research grants related to ADHD from the EU, the National Institute for Health Research (NIHR) UK, National Health and Medical Research Council (NHMRC) Australia, the Murdoch Children’s Research Institute (Australia),Department of Health (UK). He has received honoraria for advisory boards/speaking from Shire, Eli Lilly, Janssen-Cilag, Medice, Novartis. He receives royalties from Oxford University Press. Prof. Coghill is a founding member and inaugural Vice-President of the Australian ADHD Professionals Association Ltd.

Roger Paterson

Committee Member. MB BS, FRCPsych, FRANZCP, Cert. Child & Adol. Psych

I have been active in the field of child, adolescent and adult ADHD for many years. In the public sector from 1989 to 1996 in child psychiatry, and in full-time general child and adult private practice thereafter, with the last few years being mostly an ADHD practice across the lifespan.

Disclosure:

Recipient of Speaker’s fee received from Janssen, Eli Lilly, Novartis, Shire and Servier. Advisory Board paid member: Eli Lilly and Shire. Conference sponsorship: Astra-Zeneca, Janssen-Cilag, Lilly, Novartis, Pfizer, Shire and Solvay.

Michele Eva Toner

Committee Member

Dr Toner works in private practice as a specialist ADHD coach. Originally trained as a teacher, she went on to develop a special interest in students who learn differently, which eventually led her to ADHD coaching.

She has 20 years’ experience in ADHD Advocacy on a state and national level and strong connections to community, academic and professional networks.

She worked with others to form the national consumer advocacy group ADHD Australia, and was a member of their inaugural board. She is co-convener of AusPAN, an email support group for ADHD Professionals.

Michele is committed to evidence-based approaches, coaching adults, adolescents and children as a member of multidisciplinary teams. Michele also trains coaches as a faculty member of the ADD Coach Academy in New York, and is a registered mentor coach.

Disclosure:

Dr Toner has given educational talks and attended meetings sponsored by Janssen-Cilag, Eli Lilly, Novartis and Shire. She has reviewed educational materials for Shire. She receives royalties from UWA Press. She receives payment from schools and universities for PD talks and student coaching.